In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein
Abstract Background Bunyumwera virus can cause 82% mortality in humans currently with no vaccine or drugs for treatment. We described an in silico multi-epitope vaccine targeting Bunyumwera virus nucleocapsid N-protein and predicted B and T cell epitopes for immunogenicity, allergenicity, toxicity,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-06-01
|
| Series: | Journal of Genetic Engineering and Biotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s43141-022-00355-y |
| _version_ | 1797203226016088064 |
|---|---|
| author | Kanaka Durga Devi Nelluri Manne Anupama Ammulu M. Lakshmi Durga Melika Sravani Vemuri Praveen Kumar Sudhakar Poda |
| author_facet | Kanaka Durga Devi Nelluri Manne Anupama Ammulu M. Lakshmi Durga Melika Sravani Vemuri Praveen Kumar Sudhakar Poda |
| author_sort | Kanaka Durga Devi Nelluri |
| collection | DOAJ |
| description | Abstract Background Bunyumwera virus can cause 82% mortality in humans currently with no vaccine or drugs for treatment. We described an in silico multi-epitope vaccine targeting Bunyumwera virus nucleocapsid N-protein and predicted B and T cell epitopes for immunogenicity, allergenicity, toxicity, and conservancy. For creating the most potent immunological response possible, docking epitopes with HLA alleles are chosen to screen them. The 3D vaccination was docked with the Toll-like receptor-8 using molecular dynamic simulations. To ensure production efficiency, the vaccine sequence was further cloned in silico in a plasmid pIB2 vector. For efficacy and safety, results must be supported in vitro and in vivo. Results The vaccine was cloned to enable expression and translation in a plasmid vector pIB2. It was expected to be antigenic, non-allergenic, and have a high binding affinity with TLR-8 in silico cloning. This multi-epitope vaccination may stimulate both innate and adaptive immunity. Conclusion The vaccine developed in this work was based on the nucleocapsid N-protein of the Bunyumwera virus and was created using a reverse vaccinology method. Further experimental validation is required to assess the vaccine’s therapeutic effectiveness and immunogenicity. |
| first_indexed | 2024-04-24T08:15:57Z |
| format | Article |
| id | doaj.art-4aae7fd43aa5414b872687a848867280 |
| institution | Directory Open Access Journal |
| issn | 2090-5920 |
| language | English |
| last_indexed | 2024-04-24T08:15:57Z |
| publishDate | 2022-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Genetic Engineering and Biotechnology |
| spelling | doaj.art-4aae7fd43aa5414b872687a8488672802024-04-17T03:24:54ZengElsevierJournal of Genetic Engineering and Biotechnology2090-59202022-06-0120111310.1186/s43141-022-00355-yIn silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N proteinKanaka Durga Devi Nelluri0Manne Anupama Ammulu1M. Lakshmi Durga2Melika Sravani3Vemuri Praveen Kumar4Sudhakar Poda5Department of Pharmaceutics and Biotechnology, KVSR Siddhartha College of Pharmaceutical SciencesDepartment of Civil Engineering, PVP Siddhartha Institute of Technology, KanuruDepartment of Pharmaceutics and Biotechnology, KVSR Siddhartha College of Pharmaceutical SciencesDepartment of Pharmaceutics and Biotechnology, KVSR Siddhartha College of Pharmaceutical SciencesDepartment of Biotechnology, Koneru Lakshmaiah UniversityDepartment of Biotechnology, Acharya Nagarjuna UniversityAbstract Background Bunyumwera virus can cause 82% mortality in humans currently with no vaccine or drugs for treatment. We described an in silico multi-epitope vaccine targeting Bunyumwera virus nucleocapsid N-protein and predicted B and T cell epitopes for immunogenicity, allergenicity, toxicity, and conservancy. For creating the most potent immunological response possible, docking epitopes with HLA alleles are chosen to screen them. The 3D vaccination was docked with the Toll-like receptor-8 using molecular dynamic simulations. To ensure production efficiency, the vaccine sequence was further cloned in silico in a plasmid pIB2 vector. For efficacy and safety, results must be supported in vitro and in vivo. Results The vaccine was cloned to enable expression and translation in a plasmid vector pIB2. It was expected to be antigenic, non-allergenic, and have a high binding affinity with TLR-8 in silico cloning. This multi-epitope vaccination may stimulate both innate and adaptive immunity. Conclusion The vaccine developed in this work was based on the nucleocapsid N-protein of the Bunyumwera virus and was created using a reverse vaccinology method. Further experimental validation is required to assess the vaccine’s therapeutic effectiveness and immunogenicity.https://doi.org/10.1186/s43141-022-00355-yBunyumwera virusMulti-epitopeNucleocaspid N-ProteinVaccine design |
| spellingShingle | Kanaka Durga Devi Nelluri Manne Anupama Ammulu M. Lakshmi Durga Melika Sravani Vemuri Praveen Kumar Sudhakar Poda In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein Journal of Genetic Engineering and Biotechnology Bunyumwera virus Multi-epitope Nucleocaspid N-Protein Vaccine design |
| title | In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein |
| title_full | In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein |
| title_fullStr | In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein |
| title_full_unstemmed | In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein |
| title_short | In silico multi-epitope Bunyumwera virus vaccine to target virus nucleocapsid N protein |
| title_sort | in silico multi epitope bunyumwera virus vaccine to target virus nucleocapsid n protein |
| topic | Bunyumwera virus Multi-epitope Nucleocaspid N-Protein Vaccine design |
| url | https://doi.org/10.1186/s43141-022-00355-y |
| work_keys_str_mv | AT kanakadurgadevinelluri insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein AT manneanupamaammulu insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein AT mlakshmidurga insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein AT melikasravani insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein AT vemuripraveenkumar insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein AT sudhakarpoda insilicomultiepitopebunyumweravirusvaccinetotargetvirusnucleocapsidnprotein |